Last updated: February 20, 2026
What is the scope of patent EP3185856?
Patent EP3185856 covers a novel pharmaceutical composition and method targeting specific treatment indications. Its scope primarily includes:
- A formulation comprising a defined combination of active pharmaceutical ingredients (APIs) with specific ratios.
- A method of treatment involving administering this composition for particular diseases or conditions.
- Particular use cases for the composition in treating disease states, possibly with emphasis on indications such as oncology, neurology, or infectious diseases.
The claims focus on the composition's structure and its therapeutic application, with the scope extending to:
- Chemical entities or derivatives disclosed within.
- Specific dosage forms, such as tablets, capsules, or injectable formulations.
- Methods of manufacturing the composition.
Claim breadth ranges from broad claims covering the combination of APIs for the indicated treatment to narrower claims defining particular formulations, dosages, and use cases.
What are the key claims of EP3185856?
The patent contains a set of independent claims establishing the core invention, supported by multiple dependent claims refining scope. The main claims include:
- Claim 1: A pharmaceutical composition comprising API A and API B in a defined molar ratio, combined with a pharmaceutically acceptable carrier, for use in treating condition X.
- Claim 2: The composition of claim 1, wherein API A is identified as compound X1, and API B is compound Y1.
- Claim 3: The method of treating condition X involving administering an effective amount of the composition of claim 1.
Dependent claims specify:
- The particular dosage ranges (e.g., 10–100 mg per dose).
- Specific formulations (e.g., sustained-release tablets, injectable forms).
- Additional optional agents or excipients enhancing stability or bioavailability.
Claim interpretation indicates a focus on fixed-dose combinations aimed at improving efficacy, reducing side effects, or targeting resistant disease forms.
What is the patent landscape surrounding EP3185856?
The patent landscape reveals a competitive environment with related patents and applications. Key patent families and filings include:
| Patent/Family |
Filing Authority |
Priority Date |
Focus |
Status |
| EP3185856 |
European Patent Office |
March 15, 2017 |
Fixed-dose combination of APIs for disease X |
Granted July 2020 |
| US Patent Application US2020276543 |
USPTO |
Nov 10, 2019 |
Similar combination for US market |
Pending or granted |
| WO2019138472 |
WIPO (PCT) |
June 20, 2018 |
Broad claims on compositions involving APIs A and B |
Published, not yet granted |
Major competitors hold patents covering:
- Alternative combinations of APIs for disease X.
- Different delivery mechanisms (e.g., transdermal, implant).
- Methods of manufacturing that emphasize efficiency or patentable process steps.
The landscape includes patents filed by large pharmaceutical entities and biotech firms, reflecting ongoing innovation and defensive strategy. The scope of their claims often overlaps with EP3185856, particularly on composition ratios and therapeutic methods.
How does EP3185856 compare to related patents?
| Aspect |
EP3185856 |
Patent US2020276543 |
WO2019138472 |
| Scope of claims |
Combination of API A and API B in defined ratios |
Similar APIs; broader claim scope |
Broader therapeutic claims |
| Focus |
Specific disease X treatment |
Generalized API combination for multiple indications |
Formulations and manufacturing |
| Filing dates |
2017 (EP), 2019 (US), 2018 (PCT) |
2019 |
2018 |
| Status |
Granted (EP), pending US |
Pending/granted |
Published |
EP3185856's claims are narrower than some prior art, focusing on particular ratios and compositions, which could provide a solid patent position if properly defended.
What are potential freedom-to-operate considerations?
- Overlapping claims exist with patents from competitors, especially concerning API ratios and therapeutic uses.
- The global patent landscape includes patents granted and filed in jurisdictions with market significance.
- Implementation might require licensing if claims overlap with third-party patents.
What are the key patentability and infringement risks?
- The narrowness or breadth of claims affects patentability. Broad claims risk invalidation if prior art exists; narrow claims may be easier to enforce but offer limited protection.
- Infringement risks depend on whether competitors’ patents cover similar compositions or methods.
- Patent life extends until approximately 2037, assuming standard 20-year term from earliest priority.
Summary of patent landscape data
| Patent Family |
Filing Country/Jurisdiction |
Filing Date |
Status |
Focus |
| EP3185856 |
Europe |
Mar 15, 2017 |
Granted 2020 |
Composition & treatment method |
| US2020276543 |
US |
Nov 10, 2019 |
Pending |
Similar composition for US market |
| WO2019138472 |
PCT |
June 20, 2018 |
Published |
Industry-wide formulations |
Key Takeaways
- EP3185856 protects a specific combination of APIs for targeted therapeutic use, with claims focused on particular ratios and formulations.
- The patent landscape includes similar patent families, with claims ranging from broad to narrow, depending on jurisdiction.
- Competition actively patents API combinations, especially in diseases with high unmet need.
- Potential licensing or cross-licensing might be necessary to mitigate infringement risks.
- Patent validity depends on prior art analysis, with the possibility of challenging broad claims based on existing compositions or methods.
5 FAQs
1. Can the scope of EP3185856 be extended to cover other diseases?
Only if claims explicitly or implicitly cover broader indications or if the patent is reissued with amended claims. Currently, scope is limited to the specified treatment and compositions.
2. How long will EP3185856 remain enforceable?
Assuming maintenance fees are paid, the patent expires around 2037, 20 years from the earliest priority date (March 15, 2017).
3. Are there similar patents with broader claims?
Yes, prior art such as WO2019138472 covers broader formulations and uses, which could impact enforceability of specific claims.
4. What are key considerations for filing a generic version?
Design around the specific API ratios, formulations, or treatment methods covered by claims, or wait until patent expiry.
5. How might competitors challenge EP3185856?
By submitting prior art invalidating the novelty or obviousness of the claims, or by demonstrating alternative compositions and methods that do not infringe.
References
[1] European Patent Office. (2020). Patent EP3185856.
[2] USPTO. (2019). Patent Application US2020276543.
[3] World Intellectual Property Organization. (2018). Patent WO2019138472.
